Par Pharmaceutical Begins Shipment of Rizatriptan Benzoate Tablets and Rizatriptan Benzoate Orally Disintegrating Tablets

    Par Pharmaceutical Begins Shipment of Rizatriptan Benzoate Tablets and
              Rizatriptan Benzoate Orally Disintegrating Tablets

PR Newswire

WOODCLIFF LAKE, N.J., Jan. 2, 2013

WOODCLIFF LAKE, N.J., Jan. 2, 2013 /PRNewswire/ --Par Pharmaceutical
Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating
subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate
tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally
disintegrating tablets. Rizatriptan benzoate tablets and rizatriptan benzoate
orally disintegrating tablets are each indicated for the acute treatment of
migraine with or without aura in adults and in pediatric patients 6 to 17
years of age. According to IMS Health data, annual U.S. sales of rizatriptan
benzoate total approximately $653 million.

Important Information About Rizatriptan Benzoate Tablets and Rizatriptan
Benzoate Orally Disintegrating Tablets
Rizatriptan benzoate is contraindicated in patients with ischemic artery
disease or other significant underlying cardiovascular disease, coronary
artery vasospasm including Prinzmetal's angina, history of stroke or transient
ischemic attack (TIA), peripheral vascular disease (PVD), ischemic bowel
disease, uncontrolled hypertension, recent use of another 5-HT[1] agonist,
ergotamine-containing medication, or ergot-type medication, hemiplegic or
basilar migraine, concurrent administration or recent discontinuation of a
MAO-A inhibitor and hypersensitivity to rizatriptan benzoate tablets or
rizatriptan benzoate orally disintegrating tablets.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty
pharmaceutical company that develops, manufactures and markets high
barrier-to-entry generic drugs and niche, innovative proprietary
pharmaceuticals through its wholly-owned subsidiary's two operating divisions,
Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other
company information, visit www.parpharm.com.

SOURCE Par Pharmaceutical Companies, Inc.

Website: http://www.parpharm.com
Contact: Stephen Mock, Par Pharmaceutical Companies, Inc., +1-201-802-4033
 
Press spacebar to pause and continue. Press esc to stop.